Key Highlights
- Parabolic Technologies, Inc. (NASDAQ:PARA) fell 41.94% after pricing a USD 13.5 million underwritten offering on November 4, 2026, reported as 4.96 million units at USD 2.72 each with warrants.
- Cenntro Inc. (NASDAQ:CENN) fell 27.12% and Innventure fell 29.01%, each with an at-the-market program in place, USD 100 million at Cenntro and up to USD 60 million at Innventure.
- Antelope Enterprise Holdings Limited (NASDAQ:AEHL) rose 78.63% despite a USD 100 million at-the-market agreement with D. Boral Capital signed on October 1, 2026 and discounted convertible notes.
- Precision BioSciences (NASDAQ:DTIL) rose 17.49% to about USD 9.54 after pricing an offering of about USD 125 million at USD 7.75, covering 10,235,077 shares and pre-funded warrants.
Parabolic Technologies, Inc. (NASDAQ:PARA): An Underwritten Deal With Warrants Attached
The steepest fall, 41.94% to USD 0.1852 in trading on November 5, 2026, per published market data, came at Parabolic Technologies, Inc. (NASDAQ:PARA), formerly Banzai International, a day after it priced a USD 13.5 million underwritten public offering. Published coverage reports 4.96 million units at USD 2.72, each carrying warrants exercisable at USD 6.80, though those terms rest on coverage rather than a final prospectus. In an underwritten deal an Investment bank buys the units and resells them, so proceeds depend on closing, and pricing is usually set at a discount. Units add new shares and warrants, and warrants can add more shares if exercised, so each holder owns a smaller slice. Shareholders also approved raising authorized shares from 350 million to 850 million, which gives room for further issuance. The quoted price sits far below the unit price, a gap not explained by published market data. Nasdaq has also issued a delisting determination, and cumulative reverse splits total 1-for-2,000. With about 11.7 million shares traded, quoted moves can reverse.
Cenntro Inc. (NASDAQ:CENN): A USD 100 Million Program Against a Tiny Market Value
At Cenntro Inc. (NASDAQ:CENN), the 27.12% drop to about USD 0.129 on 3.79 million shares followed an at-the-market program of up to USD 100 million, with a 3.5% commission, disclosed on October 9, 2026, weeks after a private Placement of about USD 57.0 million completed in mid-September. An at-the-market program sells new shares into the open market at prevailing prices, which raises cash but dilutes holders, and the company has not said how much it has sold. Published market data puts Market Value near USD 2.27 million, far below the program ceiling, and the quoted price is far below the USD 3.90 close of October 8, 2026, a gap the filings reviewed do not reconcile. A 1-for-60 reverse split in April 2026 restored bid price compliance on April 28, 2026. Second quarter Revenue was about USD 6.2 million against a net loss of about USD 10.6 million, with cash near USD 4.3 million at June 30, 2026. A third quarter report had not been located. A small float means quoted moves can reverse.
Antelope Enterprise Holdings Limited (NASDAQ:AEHL): Rally in Spite of Two Financing Tools
The 78.63% gain at Antelope Enterprise Holdings Limited (NASDAQ:AEHL), to USD 11.20, came without a company announcement located for November 5, 2026, despite two financing tools in place. On October 1, 2026 the company signed an agreement with D. Boral Capital for an at-the-market program of up to USD 100 million of Class A shares, with proceeds for general corporate purposes. In September 2026 it closed USD 6.0 million of 8.00% convertible notes, net proceeds about USD 5.965 million. The notes convert at 80% of the lowest daily volume-weighted average price over three trading days, subject to a Nasdaq 19.99% cap and a registration limit of 12,000,000 shares, so holders gain from converting and selling at a discount. Cash was reported near USD 1.78 million, small against the program size, while first-half revenue fell to USD 29.9 million from USD 48.7 million. A 1-for-16 reverse split on August 7, 2026 left about 1,309,197 shares. Published coverage describes an October 14, 2026 spike to about USD 30.60 that closed near USD 11.49.
Innventure, Inc. (NASDAQ:INV): Funding Stress Behind an Offering Program
At Innventure, Inc. (NASDAQ:INV), the 29.01% fall to about USD 0.1534 on 4.52 million shares came days after a Strategic Review Committee was formed on November 2, 2026, citing near-term parent-company Liquidity needs. The company set up an at-the-market program of up to USD 60 million on October 6, 2026, as an alternative to a USD 75 million 2023 Equity purchase agreement, and said it does not intend to use it for Accelsius at current prices or to raise the full amount. The standby agreement remains another route that keeps dilution open. The committee oversees interim funding for AeroFlexx, which is pursuing a sale or interim third-party financing, and Refinity, funded through year-end. Accelsius, which holds most consolidated cash, has engaged Evercore Group to explore private capital. Headcount fell from 40 to 15 since the end of the first quarter. The release gave no Debt or total cash figures, so results due November 12, 2026 are the first full look, and with a market value near USD 13.31 million quoted moves can reverse.
Precision BioSciences (NASDAQ:DTIL): A Large Raise That Lifted the Shares
The 17.49% gain at Precision BioSciences (NASDAQ:DTIL), to about USD 9.54 on Volume 5.79 times normal, came as the company priced an underwritten offering of about USD 125 million at USD 7.75 per share on November 5, 2026, with closing expected on or about November 6, 2026. It covers 10,235,077 common shares plus pre-funded warrants for up to 5,893,964 shares, priced at USD 7.749995, led by TD Cowen and Guggenheim Securities. A pre-funded Warrant lets an investor pay almost the full price now and exercise later for a nominal sum, helping holders stay under an ownership threshold. Simple arithmetic gives roughly 16.1 million new shares and USD 125 million, close to half of the USD 266.51 million market value in published market data, so dilution is material. Proceeds are earmarked for PBGENE-HBV and PBGENE-DMD, plus general corporate purposes. The company did not say why shares rose despite the raise, so the reason is not confirmed. Gene editing carries trial and regulatory risks, and a quoted intraday gain can reverse.
Where Things Stand
Offerings and share programs dilute existing holders, and the balance of evidence says the market response depends on the size of the raise against the company, the use of proceeds and the quality of the buyers. Parabolic Technologies, Inc. (NASDAQ:PARA) fell on an underwritten deal and a delisting determination. Cenntro Inc. (NASDAQ:CENN) fell under a standing program. Innventure, Inc. (NASDAQ:INV) fell with another in place. Antelope rose despite one, and Precision BioSciences rose after a large raise from specialist funds. Nothing here implies a continued move in either direction. Next markers are the Nasdaq hearing, the Innventure results on November 12, 2026, the closing of the Precision BioSciences (NASDAQ:DTIL) offering and disclosures on at-the-market usage.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...